Masahiro Aoki

List of Publications by Year
in descending order

51	4,869	172457	189892
papers	citations	29 h-index	50 g-index

51	51	51	7161
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Synthetic lethality between MyD88 loss and mutations in Wnt/Î²-catenin pathway in intestinal tumor epithelial cells. Oncogene, 2021, 40, 408-420.	5.9	11
2	Inhibition of Gli2 suppresses tumorigenicity in glioblastoma stem cells derived from a de novo murine brain cancer model. Cancer Gene Therapy, 2021, 28, 1339-1352.	4.6	13
3	MYB mediates downregulation of the colorectal cancer metastasis suppressor heterogeneous nuclear ribonucleoprotein Lâ€like during epithelialâ€mesenchymal transition. Cancer Science, 2021, 112, 3846-3855.	3.9	4
4	Stromal iodothyronine deiodinase 2 (<scp>DIO</scp>2) promotes the growth of intestinal tumors in Apc^{Î”716} mutant mice. Cancer Science, 2019, 110, 2520-2528.	3.9	17
5	TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation. Oncogene, 2019, 38, 1966-1978.	5.9	19
6	Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms. Cancer Chemotherapy and Pharmacology, 2019, 83, 107-113.	2.3	7
7	Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET. Cancer Chemotherapy and Pharmacology, 2019, 83, 43-52.	2.3	12
8	HNRNPLL, a newly identified colorectal cancer metastasis suppressor, modulates alternative splicing of CD44 during epithelial-mesenchymal transition. Gut, 2018, 67, 1103-1111.	12.1	61
9	<scp>HNRNPLL</scp> stabilizes <scp>mRNA</scp> for <scp>DNA</scp> replication proteins and promotes cell cycle progression in colorectal cancer cells. Cancer Science, 2018, 109, 2458-2468.	3.9	13
10	Oncogenic Roles of the PI3K/AKT/mTOR Axis. Current Topics in Microbiology and Immunology, 2017, 407, 153-189.	1.1	242
11	Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7697-E7706.	7.1	270
12	Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma. Oncogene, 2017, 36, 6480-6489.	5.9	27
13	Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin. Anticancer Research, 2017, 37, 5235-5239.	1.1	10
14	Association between ABCG2 and SLCO1B1 polymorphisms and adverse drug reactions to regorafenib: a preliminary study. International Journal of Clinical Pharmacology and Therapeutics, 2017, 55, 409-415.	0.6	9
15	Genomic Loss of DUSP4 Contributes to the Progression of Intraepithelial Neoplasm of Pancreas to Invasive Carcinoma. Cancer Research, 2016, 76, 2612-2625.	0.9	42
16	Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc Î”716 mice involves stromal COX â€2. Cancer Science, 2015, 106, 692-699.	3.9	9
17	Transcription factors c-Myc and CDX2 mediate E-selectin ligand expression in colon cancer cells undergoing EGF/bFGF-induced epithelialâ€“mesenchymal transition. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7776-7781.	7.1	139
18	Induction of 6-sulfated glycans with cell adhesion activity via T-bet and GATA-3 in human helper T cells. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 841-848.	2.4	5

#	Article	IF	Citations
19	Sialic acid cyclization of human Th homing receptor glycan associated with recurrent exacerbations of atopic dermatitis. Journal of Dermatological Science, 2012, 68, 187-193.	1.9	3
20	JNK Signaling Promotes Intestinal Tumorigenesis Through Activation of mTOR Complex 1 in ApcÎ”716 Mice. Gastroenterology, 2011, 140, 1556-1563.e6.	1.3	35
21	Suppression of Colon Cancer Metastasis by Aes through Inhibition of Notch Signaling. Cancer Cell, 2011, 19, 125-137.	16.8	183
22	Suppression of Colonic Polyposis by Homeoprotein CDX2 through its Nontranscriptional Function that Stabilizes p27Kip1. Cancer Research, 2011, 71, 593-602.	0.9	34
23	Use of Genetically Engineered Mouse Models in Identification and Validation of Therapeutic Targets for Colon Cancer. , 2011, , 143-163.		1
24	LKB1 Suppresses p21-activated Kinase-1 (PAK1) by Phosphorylation of Thr109 in the p21-binding Domain. Journal of Biological Chemistry, 2010, 285, 18283-18290.	3.4	32
25	Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13063-13068.	7.1	154
26	CDX Transcription Factors Positively Regulate Expression of Solute Carrier Family 5, Member 8 in the Colonic Epithelium. Gastroenterology, 2010, 138, 627-635.	1.3	24
27	The role of mTORC1 pathway in intestinal tumorigenesis. Cell Cycle, 2009, 8, 3684-3687.	2.6	17
28	Hepatocellular carcinoma development induced by conditional Î²â€catenin activation in Lkb1^{+/â^’} mice. Cancer Science, 2009, 100, 2046-2053.	3.9	32
29	Matrix metalloproteinase 7 is required for tumor formation, but dispensable for invasion and fibrosis in SMAD4-deficient intestinal adenocarcinomas. Laboratory Investigation, 2009, 89, 98-105.	3.7	32
30	Reduced Level of Smoothened Suppresses Intestinal Tumorigenesis by Down-Regulation of Wnt Signaling. Gastroenterology, 2009, 137, 629-638.	1.3	59
31	Activated macrophages promote Wnt signalling through tumour necrosis factor-Î± in gastric tumour cells. EMBO Journal, 2008, 27, 1671-1681.	7.8	252
32	Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in Apc ^{Î”716} mice. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13544-13549.	7.1	148
33	Suppression of Tubulin Polymerization by the LKB1-Microtubule-associated Protein/Microtubule Affinity-regulating Kinase Signaling. Journal of Biological Chemistry, 2007, 282, 23532-23540.	3.4	51
34	Chromosomal instability by Î²-catenin/TCF transcription in APC or Î²-catenin mutant cells. Oncogene, 2007, 26, 3511-3520.	5.9	74
35	SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nature Genetics, 2007, 39, 467-475.	21.4	258
36	Triple Layer Control: Phosphorylation, Acetylation and Ubiquitination of FOXO Proteins. Cell Cycle, 2005, 4, 908-913.	2.6	272

#	Article	IF	Citations
37	Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13613-13617.	7.1	199
38	Partial oncogenic transformation of chicken embryo fibroblasts by Jun dimerization protein 2, a negative regulator of TRE- and CRE-dependent transcription. Oncogene, 2003, 22, 2151-2159.	5.9	29
39	Oncogenic transformation by Î²-catenin: deletion analysis and characterization of selected target genes. Oncogene, 2002, 21, 6983-6991.	5.9	27
40	Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene, 2001, 20, 4419-4423.	5.9	97
41	The growth-promoting activity of the Bad protein in chicken embryo fibroblasts requires binding to protein 14-3-3. Oncogene, 2001, 20, 5087-5092.	5.9	20
42	A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 136-141.	7.1	141
43	Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 1749-1753.	7.1	489
44	The Catalytic Subunit of Phosphoinositide 3-Kinase: Requirements for Oncogenicity. Journal of Biological Chemistry, 2000, 275, 6267-6275.	3.4	74
45	Nuclear endpoint of Wnt signaling: Neoplastic transformation induced by transactivating lymphoid-enhancing factor 1. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 139-144.	7.1	167
46	Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2077-2081.	7.1	242
47	The Akt kinase: Molecular determinants of oncogenicity. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 14950-14955.	7.1	270
48	Transformation of Chicken Cells by the Gene Encoding the Catalytic Subunit of PI 3-Kinase. Science, 1997, 276, 1848-1850.	12.6	398
49	The MurinecotProto-oncogene: Genome Structure and Tissue-specific Expression. Japanese Journal of Cancer Research, 1993, 84, 518-525.	1.7	13
50	Eradication of metastatic tumour cells from lymph nodes by local administration of anti-CD3 antibody. Cancer Immunology, Immunotherapy, 1993, 36, 357-363.	4.2	8
51	Association of immunoglobulin G Fc receptor II with Src-like protein-tyrosine kinase Fgr in neutrophils.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 6305-6309.	7.1	124